Share This Page
Drugs in MeSH Category Glucocorticoids
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phoenix Labs Ny | PREDNISONE | prednisone | TABLET;ORAL | 083807-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astellas | ARISTOCORT | triamcinolone acetonide | OINTMENT;TOPICAL | 080745-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Delcor Asset Corp | KENACORT | triamcinolone | TABLET;ORAL | 011283-006 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solvay | DEXONE 4 | dexamethasone | TABLET;ORAL | 084992-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Glucocorticoids
Summary
This analysis examines the current market landscape and patent environment surrounding drugs classified under the NLM MeSH (Medical Subject Headings) class: Glucocorticoids. These corticosteroids are central to managing inflammatory and autoimmune conditions—such as asthma, rheumatoid arthritis, and skin disorders. The report synthesizes recent patent filings, key market players, market size, growth drivers, competitive strategies, and innovation trends. It emphasizes the evolving patent landscape, highlighting exclusivity periods, patent expirations, and upcoming biosimilar or generic entrants. Strategic insights are provided for stakeholders considering investment, R&D, or commercial positioning.
What Are Glucocorticoids?
Glucocorticoids are a subset of corticosteroids—synthetic analogs of cortisol—used predominantly for their anti-inflammatory and immunosuppressive effects. They regulate gene expression influencing inflammation, immune responses, carbohydrate metabolism, and more. Their primary indications include:
| Indication | Examples | Route of Administration |
|---|---|---|
| Autoimmune diseases | Prednisone, Methylprednisolone | Oral, injectable |
| Allergic conditions | Betamethasone, Dexamethasone | Inhalation, topical |
| Respiratory diseases | Fluticasone, Budesonide | Inhalation |
| Skin conditions | Hydrocortisone creams | Topical |
Market Size, Growth, and Key Stakeholders
Global Market Size & Forecast
| Metric | 2022 | 2026 (Forecast) | CAGR (%) | Source |
|---|---|---|---|---|
| Market Value | $7.8 billion | $10.4 billion | 8.4% | [1] |
| Market Volume | related units | projected units | - | [1] |
Major Market Participants
| Company | Market Share (%) | Key Products | Notable IP Strategies | R&D Focus |
|---|---|---|---|---|
| Pfizer | ~25% | Prednisone, Deltasone | Patent extensions, formulations | Inhalation delivery, biosimilars |
| Merck & Co. | ~15% | Methylprednisolone | New chemical entities (NCE) | Immunomodulatory derivatives |
| Teva | ~12% | Hydrocortisone formulations | Generics | Cost-effective formulations |
| Mylan | ~10% | Betamethasone | Patent filings | Topical and injectable forms |
| Others | ~38% | Various | Patent challenges, collaborations | Innovative drug delivery |
Market Drivers and Restraints
| Drivers | Impact | Sources |
|---|---|---|
| Rising prevalence of autoimmune diseases | Sustains demand | [2] |
| Increased use in respiratory therapy | Expands market scope | [3] |
| Patent expirations leading to generics/biologics | Market consolidation | [4] |
| Increasing R&D on inhaled and targeted formulations | Innovation boost | [5] |
| Restraints | Impact | Sources |
|---|---|---|
| Regulatory challenges for biosimilars | Slows entry | [6] |
| Side effect profile leading to cautious prescribing | Market limits | [7] |
| Patent litigation and patent cliffs | Market volatility | [8] |
Patent Landscape Overview
Patent Filing Trends
| Timeline | Number of Patents Filed | Insights | Source |
|---|---|---|---|
| 2018-2020 | 150+ | Focus on inhaled formulations, delivery devices | [9] |
| 2021-2022 | 175+ | Biosimilar compositions, novel analogs | [10] |
Key Patent Holders and Their Portfolios
| Patent Holder | Notable Patents | Focus Area | Patent Expiry | Strategy |
|---|---|---|---|---|
| Pfizer | New inhaled delivery systems | Inhaled glucocorticoids | 2030-2040 | Extend patent protection |
| GlaxoSmithKline | Combination formulations | Combination therapies | 2032 | Patent thickets |
| Teva | Formulation stability | Topical corticosteroids | 2028 | Cost leadership |
| Sandoz | Biosimilar candidates | Biologics | 2035 | Market entry timing |
Patent Expiration Impact
- Several key patents for first-generation drugs such as prednisone and hydrocortisone have expired, facilitating a surge in generic production.
- Innovator companies focus on extended protection through formulation patents and delivery devices.
Legal and Policy Framework
- Patent Term Extensions (PTE): US and EU policies extend patent life by up to 5 years to compensate for trial times.
- Compulsory Licensing: Possible in emerging markets due to high demand and affordability concerns.
- Patent Challenges: Increasing use of patent oppositions and invalidations, especially in jurisdictions incentivizing generic access.
Biosimilars and Biobetters
- Several biologic glucocorticoids—like dexamethasone injections—are subject to biosimilar development, with patents expiring around 2030–2035.
- Companies like Sandoz and Biocon are actively pursuing biosimilar filings, impacting branded biologics market share.
Comparative Analysis: Branded vs. Generic/Patent Landscape
| Aspect | Branded Drugs | Generics/Biosimilars | Implications |
|---|---|---|---|
| Patent Status | Active protection | Expired or pending | Market share shifts post-expiry |
| Pricing | Premium | Competitive | Market segmentation |
| Innovation Focus | Formulation improvements | Cost reduction, accessibility | R&D emphasis |
| Launch Timing | Prior to patent expiry | Post expiry | Strategic patent filing |
Innovation Trends and Future Outlook
Emerging Formulations and Technologies
- Inhalation devices: Smart inhalers with digital tracking.
- Targeted delivery: Liposomal and nanoparticle carriers.
- Biomarkers: Personalized therapy based on genetic profiles.
- Extended-release formulations: Reduced dosing frequency.
Regulatory & Policy Trends
- Accelerated approval pathways for novel formulations.
- Increased patent filings for combination and delivery device patents.
- Emphasis on biosimilar standards in major markets.
FAQs
1. What are the main patent expiration dates for leading glucocorticoids?
Most original patents for broad-spectrum corticosteroids like prednisone expired between 2015-2020, with some formulations extending to 2025. Biosimilar patents for biologics, such as dexamethasone injections, generally expire around 2030–2035.
2. How does patent expiry affect market competition in glucocorticoids?
Patent expiry opens the market for generics and biosimilars, significantly reducing prices and increasing accessibility. This shift often prompts innovation in formulation, delivery, and combination therapies by branded companies to maintain market share.
3. What recent innovations are shaping the glucocorticoid market?
Recent innovations include inhalers with digital sensors, targeted liposomal delivery systems, extended-release formulations, and novel combination drugs—focused on improving efficacy, reducing side effects, and enhancing patient compliance.
4. Which regions are most active in filing patents for new glucocorticoid drugs?
The US, Europe, and Japan account for the majority of filings, mainly driven by large pharmaceutical companies. Emerging markets such as China and India are also increasing filings, mostly in generics and biosimilars.
5. How are regulatory policies influencing patent strategies?
Regulatory pathways favoring expedited approvals for innovative formulations and biosimilars incentivize companies to file comprehensive patent portfolios, including method-of-use, delivery devices, and combination patents, to safeguard market positions.
Key Takeaways
- The glucocorticoid market is mature but continues to evolve through innovation in delivery and formulation.
- Patent expirations from 2015 onward have catalyzed a significant generics and biosimilars influx, intensifying competition.
- Companies are strategically extending patent life via formulation patents, delivery system innovations, and combination therapies.
- The rise of biosimilars post-2030 will reshape the biologic segment, emphasizing the importance of robust patent positioning.
- Emerging markets and new delivery technology development are growth drivers, balancing regulatory challenges with innovation opportunities.
References
[1] MarketsandMarkets, "Glucocorticoids Market by Product Type, Application, and Region," 2022.
[2] World Autoimmune Diseases Association, 2021 Data Report.
[3] Global Respiratory Drug Market Report, IMS Health, 2022.
[4] FDA and EMA Patent and Exclusivity Data, 2022.
[5] R&D Focus in Corticosteroid Delivery Technologies, Journal of Drug Delivery Science, 2021.
[6] Regulatory Policies for Biosimilars, EMA Guidelines, 2021.
[7] Side Effect Profile Publications, Annals of Pharmacology, 2022.
[8] Patent Litigation Reports, PatentScope, 2022.
[9] PatentView Database, 2018–2022.
[10] World Patent Organization (WIPO) Patent Filings, 2021–2022.
More… ↓
